CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 120 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.78 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $60,283,978 | +47.5% | 4,043,191 | +8.3% | 2.01% | +70.0% |
Q2 2023 | $40,879,142 | +20.1% | 3,733,255 | -4.4% | 1.18% | +17.7% |
Q1 2023 | $34,036,384 | +665.7% | 3,903,255 | +450.5% | 1.00% | +704.0% |
Q4 2022 | $4,445,386 | -42.9% | 708,993 | -53.4% | 0.12% | -40.5% |
Q3 2019 | $7,784,000 | -71.9% | 1,520,355 | -60.6% | 0.21% | -66.9% |
Q2 2019 | $27,657,000 | -50.6% | 3,862,821 | -8.3% | 0.64% | -59.8% |
Q1 2019 | $55,946,000 | +188.6% | 4,212,821 | +71.1% | 1.58% | +113.8% |
Q4 2018 | $19,382,000 | -36.2% | 2,462,821 | -10.2% | 0.74% | -9.2% |
Q3 2018 | $30,390,000 | -17.4% | 2,742,821 | 0.0% | 0.81% | -15.8% |
Q2 2018 | $36,808,000 | +9.1% | 2,742,821 | -2.1% | 0.96% | +2.1% |
Q1 2018 | $33,745,000 | +36.6% | 2,802,821 | +4.4% | 0.94% | +15.4% |
Q4 2017 | $24,710,000 | -34.8% | 2,685,882 | -42.9% | 0.82% | +13.1% |
Q3 2017 | $37,896,000 | – | 4,701,764 | – | 0.72% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |